{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:39:57Z","timestamp":1761395997513},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A high-performance thin-layer chromatographic method was developed and validated for the concurrent determination of simeprevir (SMV) and sofosbuvir (SOF). The chromatographic separation was attained on silica gel 60 F254 as stationary phase and ethyl acetate\u2013hexane\u2013methanol (5.0:4.0:1.0, v\/v\/v) as developing solvent with UV detection at 273 nm. The RF values were 0.67\u00b10.02 and 0.43\u00b10.02 for SMV and SOF, respectively. The method has been validated in respect to the guidelines of the International Conference on Harmonization. Linearity was maintained between 60\u20131,000 and 70\u20131,200 ng\/band for SMV and SOF, respectively, with good correlation coefficients (0.9993\u20130.9997) for both drugs. The suggested method was highly sensitive as the calculated detection limits were 15 and 22 ng\/band, while the quantitation limits were 44 and 66 ng\/ band for SMV and SOF, respectively. The suggested methodology has been effectively employed for the determination of the mentioned drugs in their pure forms and their pharmaceutical dosage forms as well as human plasma without significant interference of the pharmaceutical excipients or plasma components.<\/jats:p>","DOI":"10.1093\/chromsci\/bmab034","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T11:08:43Z","timestamp":1617448123000},"page":"576-583","source":"Crossref","is-referenced-by-count":5,"title":["Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma"],"prefix":"10.1093","volume":"59","author":[{"given":"Bassam Shaaban","family":"Mohammed","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayed M","family":"Derayea","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal E","family":"Hamad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"2021070819424915800_ref1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/liv.12424","article-title":"Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir","volume":"34","author":"Asselah","year":"2014","journal-title":"Liver International"},{"issue":"3","key":"2021070819424915800_ref2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Panel","year":"2015","journal-title":"Hepatology"},{"issue":"13","key":"2021070819424915800_ref3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"9286","key":"2021070819424915800_ref4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"The Lancet"},{"issue":"20","key":"2021070819424915800_ref5","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"9916","key":"2021070819424915800_ref6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"The Lancet"},{"issue":"3","key":"2021070819424915800_ref7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"9956","key":"2021070819424915800_ref8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"The Lancet"},{"issue":"1","key":"2021070819424915800_ref9","first-page":"38","article-title":"Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation","volume":"7","author":"Issa","year":"2016","journal-title":"International Journal of Organ Transplantation Medicine"},{"key":"2021070819424915800_ref10","author":"Albrecht"},{"key":"2021070819424915800_ref11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI-MS\/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021070819424915800_ref12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC\u2013MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"Journal of Chromatography B"},{"issue":"12","key":"2021070819424915800_ref13","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1128\/AAC.01693-15","article-title":"Validation and application of a liquid chromatography-tandem mass spectrometry method to determine the concentrations of sofosbuvir anabolites in cells","volume":"59","author":"Rower","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"119","key":"2021070819424915800_ref14","doi-asserted-by":"crossref","first-page":"98269","DOI":"10.1039\/C5RA20233G","article-title":"Quantitative performance of online SPE-LC coupled to Q-Exactive for the analysis of sofosbuvir in human plasma","volume":"5","author":"Qu","year":"2015","journal-title":"RSC Advances"},{"issue":"23","key":"2021070819424915800_ref15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10337-016-3179-9","article-title":"RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies","volume":"79","author":"Zaman","year":"2016","journal-title":"Chromatographia"},{"issue":"2","key":"2021070819424915800_ref16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/22297928.2017.1325331","article-title":"Application of TLC Densitometric method for simultaneous estimation of the newly co-formulated antiviral Agents Ledipasvir and Sofosbuvir in their tablet dosage form","volume":"7","author":"Salama","year":"2017","journal-title":"Analytical Chemistry Letters"},{"key":"2021070819424915800_ref17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.saa.2018.07.018","article-title":"Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing","volume":"205","author":"EL-Shorbagy","year":"2018","journal-title":"Spectrochimica Acta A"},{"issue":"6","key":"2021070819424915800_ref18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/22297928.2016.1265468","article-title":"Innovative spectrophotometric methods for determination of newly discovered combination for hepatitis C treatment","volume":"6","author":"Abdelwahab","year":"2016","journal-title":"Analytical Chemistry Letters"},{"issue":"4","key":"2021070819424915800_ref19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.5740\/jaoacint.16-0330","article-title":"Spectrophotometric methods for simultaneous determination of Sofosbuvir and Ledipasvir (HARVONI tablet): Comparative study with two generic products","volume":"100","author":"Abo-Talib","year":"2017","journal-title":"Journal of AOAC International"},{"issue":"2","key":"2021070819424915800_ref20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/22297928.2017.1410441","article-title":"UV-spectrophotometric and stability indicating RP-HPLC methods for the determination of the hepatitis C virus inhibitor Sofosbuvir in tablet dosage form","volume":"8","author":"Hassouna","year":"2018","journal-title":"Analytical Chemistry Letters"},{"key":"2021070819424915800_ref21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpba.2016.01.019","article-title":"Development of a simple HPLC\u2013UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma","volume":"121","author":"Nannetti","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"1","key":"2021070819424915800_ref22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/22297928.2017.1287004","article-title":"Stability-indicating HPLC-DAD method for the determination of Simeprevir","volume":"7","author":"Attia","year":"2017","journal-title":"Analytical Chemistry Letters"},{"key":"2021070819424915800_ref23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC\u2013MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021070819424915800_ref24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2014.02.028","article-title":"Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"958","author":"Vanwelkenhuysen","year":"2014","journal-title":"Journal of Chromatography B"},{"key":"2021070819424915800_ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2019.04.048","article-title":"A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study","volume":"1120","author":"Ferrari","year":"2019","journal-title":"Journal of Chromatography B"},{"issue":"1","key":"2021070819424915800_ref26","first-page":"16","article-title":"Different spectral data processing techniques for determination of ledipasvir and sofosbuvir in their pure and dosage forms; a comparative study","volume":"5","author":"Salama","year":"2018","journal-title":"International Journal of Science"},{"key":"2021070819424915800_ref27","doi-asserted-by":"crossref","first-page":"104372","DOI":"10.1016\/j.microc.2019.104372","article-title":"Sensitive spectrofluorimetric assay based on micelle enhanced protocol for the determination of hepatitis C antiviral agent (simeprevir): Application to dosage form and human plasma","volume":"152","author":"Mohammed","year":"2020","journal-title":"Microchemical Journal"},{"issue":"9","key":"2021070819424915800_ref28","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.5958\/0974-360X.2018.00763.1","article-title":"Visible spectrophotometric estimation of Simeprevir in pharmaceutical formulations","volume":"11","author":"Raju","year":"2018","journal-title":"RJPT"},{"key":"2021070819424915800_ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.saa.2017.08.066","article-title":"Different spectrophotometric methods applied for the analysis of simeprevir in the presence of its oxidative degradation product: Acomparative study","volume":"190","author":"Attia","year":"2018","journal-title":"Spectrochimica Acta A"},{"key":"2021070819424915800_ref30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.saa.2018.07.017","article-title":"Simultaneous quantification of simeprevir sodium: A hepatitis C protease inhibitor in binary and ternary mixtures with sofosbuvir and\/or ledipasvir utilizing direct and H-point standard addition strategies","volume":"210","author":"Mohamed","year":"2019","journal-title":"Spectrochimica Acta A"},{"issue":"8","key":"2021070819424915800_ref31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/ac60092a004","article-title":"Graphical absorbance-ratio method for rapid two-component spectrophotometric analysis","volume":"26","author":"Hirt","year":"1954","journal-title":"Analytical Chemistry Letters"},{"key":"2021070819424915800_ref32","volume-title":"Thin-layer chromatography: techniques and applications","author":"Fried","year":"1982"},{"key":"2021070819424915800_ref33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.talanta.2017.08.051","article-title":"Innovative thin-layer chromatographic method combined with fluorescence detection for specific determination of Febuxostat: Application in biological fluids","volume":"176","author":"Mohamed","year":"2018","journal-title":"Talanta"},{"key":"2021070819424915800_ref34","volume-title":"Validation of analytical procedures: text and methodology Q2 (R1)","author":"Guideline","year":"2005"},{"key":"2021070819424915800_ref35","volume-title":"United States Pharmacopeia and National Formulary (USP 37\u2013NF 32)","author":"Pharmacopeia","year":"2014"},{"issue":"12","key":"2021070819424915800_ref36","doi-asserted-by":"crossref","first-page":"e01217","DOI":"10.1128\/AAC.01217-17","article-title":"Pharmacokinetic interactions between simeprevir and ledipasvir in treatment-naive hepatitis C virus genotype 1-infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen","volume":"61","author":"Bourgeois","year":"2017","journal-title":"Antimicrob Agents Ch"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/59\/6\/576\/37975637\/bmab034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/59\/6\/576\/37975637\/bmab034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:15:51Z","timestamp":1625800551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/59\/6\/576\/6211380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,6]]},"published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmab034","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,4,6]]}}}